gefitinib + cisplatin + radiotherapy

Gefitinib + cisplatin + radiotherapy is a combination regimen used primarily in the treatment of locally advanced cancers, such as head and neck squamous cell carcinoma and esophageal carcinoma. Gefitinib is an oral small molecule inhibitor targeting the epidermal growth factor receptor (EGFR) tyrosine kinase, thereby blocking EGFR-mediated signaling pathways involved in tumor cell proliferation and survival. Cisplatin is a platinum-based chemotherapeutic agent that induces DNA crosslinking, leading to apoptosis of rapidly dividing cells. Radiotherapy uses ionizing radiation to damage DNA in cancer cells, further enhancing cytotoxicity. Preclinical studies have shown synergistic effects when combining these agents, with clinical trials demonstrating feasibility and tolerability for this regimen[1][2][3][4]. The combination aims to improve response rates by simultaneously inhibiting EGFR signaling, inducing DNA damage through chemotherapy, and maximizing local tumor control with radiation.

Other names

ZD1839ZD-1839ZD 1839CDDP